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Objective: Myoepithelial carcinoma (MC) of head and neck is extremely rare. The relevant
literature consists only of case reports, and consequently many of its clinical characteristics and
optimal treatment strategies remain unknown.
Methods: We retrospectively analyzed 23 patients diagnosed with MC of the head and neck
between 1991 and 2005. Most patients were treated with surgery and postoperative radio-
therapy or adjuvant chemotherapy. The recurrence, survival and local control rates were
evaluated.
Results: Thirteen (56.5%) patients were male and 10 were female with a median age of 52
years (range: 15–77 years). The parotid was the most frequently involved site (39.1%). Eighteen
patients underwent surgery as their initial treatment and nine of these received postoperative
radiotherapy. The 3-year and 5-year overall survival rates were 59% and 31.8%, respectively.
The local relapse rate was 30.4% (6/23); eight patients had a distal metastasis, and the lung was
the most common site. There was no difference in the local control and survival rates between
patients who received surgery alone and those with additional postoperative radiotherapy
(p=0.059). Two patients had partial response after chemotherapy with dacarbazine..08.002
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25Myoepithelial carcinoma of the head and neck: A report of 23 cases and literature reviewConclusions: The detailed clinical data presented here reveal several new characteristics of
MC of the head and neck. Postoperative radiotherapy did not improve the prognosis.
Chemotherapeutic regimens that include dacarbazine might be useful.
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Myoepithelial carcinoma (MC), also known as malignant
myoepithelioma, is a rare neoplasm that was ﬁrst described
in 1975 by Stromeyer et al. [1]. MC was deﬁned as a solitary
pathological diagnosis in 1991 by the World Health Organi-
zation (WHO) [2,3], and its deﬁnition was updated in 2005
[4]. MC primarily originates from the tissues of the head and
neck, and most cases arise from salivary gland tissues and
the parotid gland in particular [4–7]. It has a relatively low
incidence, accounting for less than 1% of malignant salivary
gland tumors [5,6]. The diagnosis is conﬁrmed by immuno-
histochemical and ultrastructural investigations. Approxi-
mately half of salivary gland MC arise in association with a
benign mixed tumor or myoepithelioma [4]. Histologically,
morphological heterogeneity is the hallmark in MC, and the
majority of neoplasms display more than one cell type [7,8].
Immunohistochemically, these tumors are mostly positive
for vimentin, S-100 protein, cytokeratin and α-smooth
muscle actin (α-SMA), and certain new myoepithelial mar-
kers have been reported to have high expression levels in
MC, such as calponin (CALP), p27, p53, CAM5.2 and epithe-
lial membrane antigen, amongst others [5–7]. Wide surgical
excision is the treatment of choice, and radiotherapy is
currently recommended for postoperative treatment when
a high risk of recurrence or metastasis exists.
Previously published literatures with regards to MC have
usually been case reports [8–12], although some large scale
series have been reported recently [13,14]. The majority of
reports on MC focus on pathological features, which are
principally concerned with the complexities of cytological
and immunohistological diagnostic criteria; in particular, the
optimal management strategy remains unclear. The beneﬁts of
radiotherapy are unknown, and the use of chemotherapy in the
adjuvant setting is unproven as a result of the small numbers of
presented cases [4,6]. This study, to our knowledge, is the most
comprehensive evaluation of the clinical features, prognosis,
and treatment outcomes of MC of the head and neck. In order
to help clarify the various uncertain aspects of the character-
istics and treatment outcomes of head and neck MC, we
retrospectively analyzed the results of detailed clinical data
on 23 consecutive patients with MC of the head and neck who
received their initial treatment at two institutes of Sun Yat-sen
University in south China over a 15-year period.
2. Patients and methods
2.1. Patients
A retrospective analysis was performed of 23 patients with MC
of the head and neck who were diagnosed and received their
initial treatment in the Cancer Center of Sun Yat-sen University
(19 patients) and the First People's Hospital of Foshan Afﬁliatedto Sun Yat-sen University (4 patients) within the past 15 years
(between January 1991 and December 2005). All pathological
materials were obtained from surgical biopsies, and the
histopathological diagnoses were made according to the WHO
classiﬁcation. A number of clinical data were analyzed based on
the clinical records, including age, gender, clinical stage,
primary site of the MC, involved lymph nodes, treatment (ﬁeld
and total dose of radiotherapy, chemotherapy regimens and
dosages) and response to initial treatment.
2.2. Treatment
All patients underwent chest X-rays, abdomen and pelvic
ultrasounds, total body bone scanning (technetium-99 m
bone scintigraphy), and computed tomography (CT) scans
or magnetic resonance images (MRI) of the head and neck.
Eighteen patients (78.2%) underwent surgery as their
initial treatment, and the remaining ﬁve patients (21.8%)
were not candidates for surgery. Of the 13 patients who
underwent radical surgery, three patients had a lateral neck
dissection due to cervical lymph node metastasis.
Nine patients (39.1%) received adjuvant radiotherapy after
surgery. The median doses to the primary site were 60 Gy
(range: 50–70 Gy), with a daily fraction of 2.0 Gy. Four patients
received cervical lymph node irradiation, where the median
dose were 52 Gy (range: 50–60 Gy) with a 2.0 Gy daily fraction.
Of the ﬁve patients who received chemotherapy, three
received the MAID regimen for sarcoma, as follows: ifosfamide
(2500 mg/m2/d, continuous intravenous, (CIV), d 1–3), doxor-
ubicin (15 mg/m2/d, CIV, d 1–4) and dacarbazine (250 mg/m2,
CIV, d 1–4), and two received pacitaxel (175 mg/m2, CIV, d1)
and carboplatin ( area under the curve (AUC)=5 or 6) with
dacarbazine dacarbazine (125 mg/m2, CIV, d 1–5), which usually
entailed between two and four cycles of chemotherapy.
2.3. Follow-up
Patients were analyzed using follow-up data up to and including
April 15th, 2010. The mean follow-up duration was 41 months
(range: 8–129 months). Patients were assessed every 2–3 months
for the ﬁrst 2 years, every 6 months for the next 3 years, and
then yearly thereafter. Each follow-up visit included a routine
physical examination, imaging (CT, MRI) of the head and neck,
and ﬁberoptic endoscopy if indicated. A chest X-ray, abdomen
and pelvic ultrasound, and total body bone scan was also
performed every 3–6 months or earlier, according to the
discretion of the treating physician.
2.4. Statistical analyses
Overall survival (OS) was deﬁned as the interval between the
dates of diagnosis and death from any cause. Progression-free
survival (PFS) was deﬁned as the interval from the date of
Fig. 1 Survival curves of 23 patients with myoepithelial
carcinoma of the head and neck.
Fig. 2 A 47-year old female patient diagnosed with myoepitheli
zygomatic arch; (B) intracranial metastasis and (C) extensive lung m
and post-adjuvant radiotherapy.
T. Xu et al.26diagnosis to the date of disease progression, relapse or death
from any cause. All survival curves were evaluated by the
Kaplan–Meier analysis method. A P-value of 0.05 or less was
considered to be indicative of statistical signiﬁcance. All
statistical analyses were performed using SPSS, version 16.0
(SPSS 16.0 for Windows) Fig. 1.3. Results
3.1. Patient characteristics
The majority of patients (n=21) presented with the primary
complaint of a painless mass in the head or neck, and the
mean duration of symptoms before presentation was
5.4 months. The ages of patients ranged from 15 to 77
years, and the median age was 52 years. There were 13
male and 10 female patients, with a male-to-female ratio of
1.3:1. The subsite distribution was the parotid gland in
39.1% (n=9), nasal cavity in 17.4% (n=4), maxillary sinus inal carcinoma. (A) Head and neck MR scan showing a mass in
etastasis were observed at three months after radical surgery
Fig. 3 Hematoxylin-eosin staining section of myoepithelial carcinoma of the head and neck at medium power ( 400) (A) and (B),
vimentin+ (C), S100 (D), SMA+ (E) and 34BE12+ in immunohistochemistry ( 400).
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were found in the nasopharynx, hard palate, submandibular
gland, pharynx and the base of tongue (4.3%, n=1). Four
patients presented with cervical lymph node metastases
from primary tumors of the parotid gland (n=3) and
submandibular gland (n=1) Fig. 2.
3.2. Histopathological characteristics
Cytologically, the lesions were composed of four cell types
of tumor cells: spindle-type (45.0%), plasmacytoid-type
(7.5%), epithelial-type (32.5%), and clear-type (2.5%). Mix-
tures of two cell types were common, and tumors with
single cell types were infrequent. Conﬁrmation of myoe-
pithelial differentiation was performed with epithelial (CK,
EMA and S100) and myogenic markers (α-SMA, HHF-35).
Immunoreactivity for S-100 protein was present in 23 out of
23 (100%) tumors, and 22 of 23 (96%) were positive for
vimentin. HHF35, CK and α-SMA were immunoreactive in
78%, 74% and 65% of tumors, respectively. CD30 and p53
were positive in three and seven tumors, respectively, and
only four tumors were positive for EMA expression Fig. 3.
3.3. Local treatment and long-term survival
All 23 patients were evaluated for their response to the
initial treatment, and OS and PFS rates were calculated.
The median follow-up period was 58 months (range: 8–129
months). The 3-year and 5-year PFS were 51.9% and 31.2%,
respectively, and the 3-year and 5-year OS were 59% and
31.8%, respectively (Fig. 1). The local relapse rate was
30.4% (6/23); eight patients had distal metastases following
treatment, and three had local relapses with concurrent
distant metastases. The lung was the most common site fora distant metastasis (n=5); other sites of distant spread
included the brain (n=3), bone (n=1), and inguinal lymph
nodes (n=1). Most recurrences occurred within the ﬁrst
3 years.
3.4. Relationship between treatment and
prognosis
Wide local excision obtained a good prognosis, and incom-
plete surgery was predictive of recurrence. Among the
patients with surgery, six received incomplete surgery, the
3-year PFS was 33.3%, which was lower than patients with
complete excision (37.4%). Of the ﬁve patients who received
chemotherapy, two patents achieved partial response (PR)
with the two cycles of the MAID regimen. Nine patients
received surgery alone and another nine received surgery
with radiotherapy. The 5-year OS rates were 44.4%, and
16.7% between these two groups (p=0.059). The addition of
postoperative radiotherapy with photons did not improve the
loco-regional control or survival rates in this series.4. Discussion
MC of the head and neck is such a rare epithelial neoplasm
that many of its clinical and treatment aspects remain
unclear. The incidence has been reported as 0.43% of
malignant salivary gland tumors [6]. Contribution of less
than 2% of all salivary gland carcinomas, occurring at a
mean age of 55 yr, with a higher incidence in women than
men [4] was reported by the WHO. In our series, the male-
to-female ratio was 1.3:1 with a mean age of 52 yr.
The salivary glands, and the parotid gland in particular,
were the most common sites for head and neck MC in previous
T. Xu et al.28case studies [5–7,13]; in our study, we found that the parotid
gland was also the most frequent site of involvement (n=9,
39.1%). With regards to the tumor cell origin, MC has been
reported to originate de novo [7], whereas others were
classiﬁed as myoepithelial carcinoma ex pleomorphic ade-
noma [15,16] or within benign myoepitheliomas [6,7,17].
Consequently, MC can be easily confused with many tumors
due to both their rarity and their morphological heterogene-
ity. MC is diagnosed by immunohistochemical and ultrastruc-
tural examinations. According to Chieng et al. [18], the
cytological features of MC are diverse and may lack overt
features of malignancy. However, Savera et al. [7] considered
that the presence of tumor inﬁltration into adjacent tissues is
the most notable feature that distinguishes from benign
myoepithelioma. Four cell types are identiﬁed in myoepithe-
lial salivary gland neoplasms: plasmacytoid, spindle, epithe-
lioid, and clear cell types [19–21]. However, there is no
correlation between the cell types and prognosis [7].
We found that a mixture of both spindle and epithelial-type
was the most common combination, and the clear cell
type was least frequently encountered. Nagao et al. [6]
described a carcinoma with osteoclast-like giant cells,
which was always associated with rapid metastasis and a
poor prognosis.
Most MC tumors express S-100 and α-SMA, which are
proteins that are usually not present in myoepithelial cells;
however, both markers are very sensitive but not speciﬁc
[7]. CEA is completely absent, which could distinguish MC
from epithelial–myoepithelial carcinoma (EMC). Recently,
Kane et al. found that immunohistochemical analysis of 51
patients with MC showed positivity for vimentin (100%), CK
(74%), EMA (27%), CD10 (62%), SMA (35%), S-100 (82%), p63
(28%), and CALP (98%), and 100% of tumors were negative
for CEA (100%) [13]. In our study, immunoreactivity for
S-100, vimentin, HHF35, CK and SMA was present in 100%,
93%, 78%, 74% and 65% of tumors respectively. Furuse et al.
[22] recommended that the best way to identify MC was by
assessing the expression of α-SMA or CALP as well as
vimentin, when the tumor was not fully differentiated.
The behavior of head and neck MC is very variable. This
tumor recurs frequently at local sites and metastases occur
commonly. Hornick et al. [23] observed that approximately
40% patients had local recurrence and 30% metastasized
postoperatively in malignant myoepithelial tumors of soft
tissues. In a recent review of 51 cases, local recurrence was
found in 18 patients, metastases were present in seven
patients, and the mean disease-free survival time was 31.9
months [13]. In the present series, the 3-year and 5-year OS
rates were 59% and 31.8%, respectively. The local relapse rate
was 30.4% (6/23), eight patients had distal metastases, and
three of these had a concomitant local relapse. The lung was
the most common site of distant spread (5/8), followed by the
brain. Yu et al. [24] found that MC could be classiﬁed as a
high-grade malignancy with a poor prognosis; in their study, 16
(59%) out of 27 cases of MC had a recurrence and six (22%)
cases of MC developed metastases. Although this study was
limited by the low patient numbers, the prognosis of these
patients appears to be similar to MC that occur in other sites.
Distant metastases of salivary MC have been reported fre-
quently and occur from several months to many years after
the initial resection [7,14]. The common sites of distant
metastases are the lungs, kidneys, brain, and skin [7,23–26].To date, there is no consensus with regards to the
treatment of head and neck MC due to its rarity. Wide
surgical excision is always the ﬁrst choice for localized
tumors [27,28]. With a high local recurrence rate, initial
surgery should be radical with sufﬁcient disease-free mar-
gins. As the most common site is the parotid gland, tumor
invasion of the facial nerve may occur. Attempts should be
made to preserve the facial nerve if the primary tumor is
small and/or is far away from the facial nerve. We found
that cervical node metastasis alone was infrequent in head
and neck MC, which is in consensus with the ﬁndings of
other authors [24]. Therefore, elective neck dissection is
not recommended routinely, and it is only applied when
large cervical nodes are present.
Radiotherapy is used as an initial therapy when there
surgery is contraindicated, or as adjuvant therapy when a
high risk of recurrence or metastasis if perceived, such as
perineural invasion or vascular embolism. Although MC was
previously perceived as radiosensitive, the beneﬁts of
radiation remain unclear from the current literature. Sou-
marová et al. [29] reported that a 90-year-old man received
palliative radiotherapy with a total dose of 62.5 Gy in 25
fractions with good response and an excellent palliative
effect. In the present series, a total of nine patients
received adjuvant radiotherapy. However, we found that
adjuvant radiotherapy did not improve local control and
survival rates. In separate case reports for MC of head and
neck by Nieder et al. [30], postoperative radiotherapy
after incomplete surgical resection also did not beneﬁt
local control and survival. A clinical study from the Peking
University of China [24] gave similar results, with eight out
of 12 patients developing a recurrence after postoperative
radiotherapy. Fang et al. found that high levels of ataxia
telangiectasia-mutated protein (ATM) might induce radio-
resistance in MC, and recommended that an accelerated,
high-dose approach should be delivered as soon as possible
after surgery [31]. We believe that changing the fraction of
radiation or using high-liner energy transmission (LET)
radiotherapy, such as carbon particles and fast neutrons,
may help to improve outcome.
With regards to chemotherapy, the literature is more
sparse. In our study, ﬁve patients received chemotherapy
and two patents got PR with the MAID regimen. Although MC
can recur and distal metastases may occur, it might be
chemosensitive to the sarcoma regimen of chemotherapy.
Takayama et al. [32] and Noronha et al. [33] reported useful
and sustained responses to intra-arterial cisplatin with
irradiation, or intravenous cisplatin/carboplatin in combi-
nation with paclitaxel in separate case reports for malignant
myoepitheliomas arising in the head and neck or vulva.
However Nieder et al. found no response to ifosfamide or
BCNU [30]. The choice of drugs was dictated by the
epithelial nature of the tumor. However, whether survival
was improved by this treatment is speculative and impos-
sible to assess.
In conclusion, MC of head and neck is a very rare tumor
with a high rate of recurrence and metastasis. Postoperative
radiotherapy did not improve prognosis in our series, but
chemotherapy could be useful in these patients. The
sarcoma regimen that includes dacarbazine might be the
optimal protocol, but further chemotherapeutic evaluation
will be needed.
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